

## Special Issue

# Advanced Strategies in the Care of Hepatocellular Carcinoma Patients

### Message from the Guest Editors

We are honored to be the of this Special Issue of *Cancers* that summarizes current research in the diagnosis and treatment of hepatocellular carcinoma (HCC). HCC is the most common primary liver cancer, with geographical variations among its prevalence. With HCC still being the leading cause of death in patients with cirrhosis, and considering the worldwide increasing incidence in patients with underlying metabolic associated liver disease, working on HCC should be one of the research priorities. In this Special Issue, we welcome papers that enhance our knowledge of innovative diagnostic and prognostic methods and discuss the results of therapeutic experimentation, including those focused on translational research. We look forward to receiving your contributions.

---

### Guest Editors

Prof. Dr. Matteo Donadon

University Maggiore Hospital, University of Piemonte Orientale, 28100 Novara, Italy

Prof. Dr. Guido Torzilli

Division of Hepatobiliary Surgery & General Surgery, Humanitas Research Hospital, 20089 Rozzano, Italy

---

### Deadline for manuscript submissions

closed (31 December 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/112004](https://mdpi.com/si/112004)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)